Drug Search Results
More Filters [+]

Barasertib

Alternative Names: barasertib, azd1152
Latest Update: 2024-05-06
Latest Update Note: PubMed Publication

Product Description

An orally bioavailable, small-molecule, dihydrogen phosphate prodrug of the pyrazoloquinazoline Aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide (AZD1152-HQPA) with potential antineoplastic activity.  (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/barasertib)

Mechanisms of Action: AURK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Barasertib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Myeloid Leukemia

Phase 2: Diffuse Large B-Cell Lymphoma|Acute Myeloid Leukemia

Phase 1: Acute Myeloid Leukemia|Oncology Solid Tumor Unspecified|Leukemia|Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AZD1152 in diffuse large B-cell lymphoma

P2

Completed

Diffuse Large B-Cell Lymphoma

2013-09-09

ORH/PID/6265

P2

Completed

Diffuse Large B-Cell Lymphoma

2013-09-01

2009-010114-30

P2

Terminated

Acute Myeloid Leukemia

2012-04-26

SPARK-AML1

P3

Completed

Acute Myeloid Leukemia

2011-06-01

Recent News Events